Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06927999 · ClinicalTrials.gov registry record · Phase 2
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
A Phase 2 study of Urticaria Chronic, sponsored by ARS Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT06927999 is a Phase 2 study of Urticaria Chronic that is actively recruiting participants, run by ARS Pharmaceuticals. The registered enrollment target is 42 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06927999, a Phase 2 study of Urticaria Chronic, is actively recruiting participants, sponsored by ARS Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 0.5 mg epinephrine
- DRUG 1 mg epinephrine
Study Locations (3)
Illinois
- Endeavor Health Clinical Trials Center - Glenview
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Other
- Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30 - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06927999
The ClinicalTrials.gov registry entry for NCT06927999 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARS Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urticaria Chronic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06927999 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Ohio, Other.
Frequently Asked Questions
What is clinical trial NCT06927999 about?
NCT06927999 is a clinical study titled "An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria". This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
What is the current status of trial NCT06927999?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2025-07-09. Estimated completion is 2026-06.
What conditions does trial NCT06927999 study?
This clinical trial studies the following conditions: Urticaria Chronic.
What interventions are being tested in trial NCT06927999?
The interventions under investigation include: Placebo (DRUG), 0.5 mg epinephrine (DRUG), 1 mg epinephrine (DRUG).
Who is sponsoring clinical trial NCT06927999?
This trial is sponsored by ARS Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06927999 being conducted?
This trial has 3 study locations across Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urticaria Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.